Therapeutics for Dengue

Masri, Mohamad Fadhli Bin; Rathore, Abhay P. S.; John, Ashley L. St.

doi:10.1007/s40506-019-00193-6

Cited by 8 publications

(5 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DENV is primarily spread by female Aedes aegypti mosquitoes, which thrive in urban habitats at subtropical and tropical latitudes ( 3 ). In the absence of broadly effective therapeutics or vaccines ( 4 – 8 ), disease control efforts have historically involved suppression of mosquito populations by removal of urban breeding habitats and insecticide/larvicide treatment ( 9 ). However, the accumulation of insecticide resistance in Ae.…”

Section: Reducing Dengue Incidence With Wolbachia -Based Biocontrol Measuresmentioning

confidence: 99%

Using Wolbachia to Eliminate Dengue: Will the Virus Fight Back?

Edenborough

Flores

Simmons

et al. 2021

J Virol

View full text Add to dashboard Cite

Recent field trials have demonstrated that dengue incidence can be substantially reduced by introgressing strains of the endosymbiotic bacterium, Wolbachia into Aedes aegypti mosquito populations. This strategy relies on Wolbachia reducing the susceptibility of Ae. aegypti to disseminated infection by positive-sense RNA viruses like dengue. However, RNA viruses are well known to adapt to antiviral pressures. Here we review the viral infection stages where selection for Wolbachia-resistant virus variants could occur. We also consider the genetic constraints imposed on viruses that alternate between vertebrate and invertebrate hosts, and the likely selection pressures that dengue virus might adapt to in order to be effectively transmitted by Ae. aegypti that carry Wolbachia. Whilst there are hurdles to dengue viruses developing resistance to Wolbachia, we suggest that long-term surveillance for resistant viruses should be an integral component of Wolbachia-introgression biocontrol programs.

show abstract

Section: Reducing Dengue Incidence With Wolbachia -Based Biocontrol Measuresmentioning

confidence: 99%

Using Wolbachia to Eliminate Dengue: Will the Virus Fight Back?

Edenborough

Flores

Simmons

et al. 2021

J Virol

View full text Add to dashboard Cite

show abstract

“…Many severe dengue symptoms are thought to result from a pathological host immune response [ 8 ]. Mast cells, in particular, have been identified as an important drug target for the treatment of severe dengue pathologies including vascular permeability, plasma leakage, and thrombocytopenia [ 89 , 90 ]. Mast cells are granulated innate immune cells located along host-environment interfaces like epithelial and endothelial barriers such that they can quickly respond to invading pathogens [ 91 ].…”

Section: Development Of Therapeutics Targeting Hostmentioning

confidence: 99%

Dengue: Update on Clinically Relevant Therapeutic Strategies and Vaccines

Kala

John

Rathore

2023

Curr Treat Options Infect Dis

Self Cite

View full text Add to dashboard Cite

Opinion statementDengue viruses (DENV) continue to circulate worldwide, resulting in a significant burden on human health. There are four antigenically distinct serotypes of DENV, an infection of which could result in a potentially life-threatening disease. Current treatment options are limited and rely on supportive care. Although one dengue vaccine is approved for dengue-immune individuals and has modest efficacy, there is still a need for therapeutics and vaccines that can reduce dengue morbidities and lower the infection burden. There have been recent advances in the development of promising drugs for the treatment of dengue. These include direct antivirals that can reduce virus replication as well as host-targeted drugs for reducing inflammation and/or vascular pathologies. There are also new vaccine candidates that are being evaluated for their safety and efficacy in preventing dengue disease. This review highlights nuances in the current standard-of-care treatment of dengue. We also discuss emerging treatment options, therapeutic drugs, and vaccines that are currently being pursued at various stages of preclinical and clinical development.

show abstract

“…To date, dengue fever has no specic treatment method, and dengue surveillance is the main strategy to prevent the outbreak of the disease. [14][15][16] Recently, numerous attempts have been made for dengue vaccination; however, the world currently has a single licenced dengue vaccine, Dengvaxia (CYD-TDV), which was developed and made accessible by Sano Pasteur. Despite the successful commercialisation of the dengue vaccine, the limitations that make it ineffective in eliciting a stable immune response against different serotypes (1-4) of dengue fever, as well as the restrictions that prevent it from being administered to children under the age of nine, limit its application.…”

Section: Introductionmentioning

confidence: 99%